Table 5 Cox regression analysis of the risk factors for renal dysfunction in the patients with pMN
From: Complement activation products in the circulation and urine of primary membranous nephropathy
Parameters | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | P value | HR (95% CI) | P value | |
Gender (male) | 2.403 (1.089–5.305) | 0.030 | 1.500 (0.448–5.015) | 0.511 |
Age | 1.031 (0.980–1.086) | 0.238 |  |  |
Nephrotic syndrome | 0.741 (0.216–2.543) | 0.634 |  |  |
Anti-PLA2R antibody positivity | 0.249 (0.032–1.945) | 0.185 |  |  |
Level of anti-PLA2R antibodies | 1.006 (1.001–1.010) | 0.020 | 1.005 (1.001–1.010) | 0.023 |
Proteinuria | 1.031 (0.879–1.209) | 0.712 |  |  |
Serum albumin | 0.983 (0.882–1.075) | 0.750 |  |  |
eGFR | 1.005 (0.988–1.023) | 0.566 |  |  |
Serum-C3 | 0.242 (0.013–4.413) | 0.338 |  |  |
Serum-C4 | 0.011 (0.00–92.092) | 0.329 |  |  |
P-C1q | 0. 721 (0.120–4.321) | 0.721 |  |  |
P-C4d | 0.213 (0.003–17.880) | 0.494 |  |  |
P-MBL | 0.983 (0.962–1.004) | 0.119 |  |  |
P-Bb | 0.000 (0.000–5820) | 0.381 |  |  |
P-Properdin | 0.090 (0.000–67.712) | 0.476 |  |  |
P-C3a | 0.990 (0.978–1.002) | 0.101 |  |  |
P-C5a | 0.989 (0.955–1.024) | 0.554 |  |  |
P-MAC | 0.924 (0.689–1.240) | 0.600 |  |  |
U-C1q | 0.642 (0.100–4.107) | 0.640 |  |  |
U-C4d | 1.026 (0.932–1.129) | 0.607 |  |  |
U-MBL | 0.739 (0.000–5,302,470) | 0.970 |  |  |
U-Bb | 1.020 (0.85–1.216) | 0.828 |  |  |
U-Properdin | 0.978 (0.922–1.037) | 0.459 |  |  |
U-C3a | 1.000 (0.998–1.022) | 0.856 |  |  |
U-C5a | 1.003 (0.995–1.011) | 0.442 |  |  |
U-MAC | 0.991 (0.859–1.144) | 0.905 |  |  |